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Despite being one of the most prevalent tropical
diseases, for many years malaria was not a commercial
priority for the pharmaceutical industry. However, in
response to the emergence and spread of resistance to
the available antimalarial drugs, there has been a renais-
sance in the discovery and development of new medi-
cines to control the disease in the last few years. The
persistent threat of resistance means that new molecules
with novel mechanisms of action are continually
required. Furthermore, the recent call for the elimina-
tion and eradication of malaria has prompted an exten-
sion of the stages of the life cycle of malaria parasites
that should be targeted by new molecules. Recent
advances in genome-based technologies and in vitro
screening of whole parasites have broadened the range
of therapeutic targets and are accelerating the develop-
ment of a new generation of treatments for both malaria
control and eradication.
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